RxDoctor Payments Data

Kari Deboo

Family · Missoula, MTNPI 1780963538

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.8% of the total across 116 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by AbbVie at 30.7% of the total. 2025 is the largest year on record at $914, 8.3 times the $111 reported in 2021. Among family clinicians in MT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,379in general payments, 2019–2025

Across 116 payments — averaging $20.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$731
  • Takeda Pharmaceuticals U.S.A., Inc.$300
  • Johnson & Johnson$266
  • Pfizer$163
  • Janssen Scientific Affairs, LLC$152
  • Regeneron Healthcare Solutions, Inc.$105
  • plus $662 from 16 others

What the payments were for

  • Food & beverage$2,27996%
  • Education$1004%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,379 in reported general payments places this provider in the 90th percentile of 481 family providers in Montana.

See all family providers in Montana

Medicare billing

Part B allowed, 2024
$162,942
Medicare patients
259
Services billed
8,760

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab35$983,985
CreonLipase/Protease/Amylase31$20,447
Budesonide DrBudesonide17$1,819
Lubiprostone21$1,586
Omeprazole106$1,161
Budesonide EcBudesonide12$1,144
Dicyclomine Hcl32$790
Sulfasalazine19$682
Pantoprazole Sodium43$615

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$266$983,98535 claims
AbbVieCreon$731$20,44731 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 481 family providers in Montana.

Other family in Missoula

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →